PD-L1 immunohistochemical detection in tumor cells and tumor microenvironment: Main considerations on the use of tissue micro arrays

International Journal of Molecular Sciences

Volumn 17, Issue 7, 2016, Pages

  Botti, Gerardo ^a   Scognamiglio, Giosuè ^a   Cantile, Monica ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

PD L1 immunohistochemical (IHC) detection; TMA; Tumor microenvironment

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOSURVEILLANCE; NOTE; PREDICTIVE VALUE; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; MELANOMA; METABOLISM; PATHOLOGY; SKIN TUMOR;

BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 85016397923     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17071046     Document Type: Note

References (10)

1. Keir, M.E.; Butte, M.J.; Freeman, G.J.; Sharpe, A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26, 677-704. [CrossRef] [PubMed]
2. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med. 2002, 8, 793-800. [CrossRef] [PubMed]
3. Wu, P.; Wu, D.; Li, L.; Chai, Y.; Huang, J. PD-L1 and survival in solid tumors: A meta-analysis. PLoS ONE 2015, 10, e0131403. [CrossRef] [PubMed]
4. Mittendorf, E.A.; Philips, A.V.; Meric-Bernstam, F.; Qiao, N.; Wu, Y.; Harrington, S.; Su, X.; Wang, Y.; Gonzales-Angulo, A.M.; Akcakanat, A. et al. PD-L1 Expression in triple-negative breast cancer. Cancer Immunol. Res. 2014, 2, 361-370. [CrossRef] [PubMed]
5. McLaughlin, J.; Han, G.; Schalper, K.A.; Carvajal-Hausdorf, D.; Pelekanou, V.; Rehman, J.; Velcheti, V.; Herbst, R.; LoRusso, P.; Rimm, D.L. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol. 2016, 1, 46-54. [CrossRef] [PubMed]
6. Muenst, S.; Schaerli, A.R.; Gao, F.; Däster, S.; Trella, E.; Droeser, R.A.; Muraro, M.G.; Zajac, P.; Zanetti, R.; Gillanders, W.E. et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 2014, 146, 15-24. [CrossRef] [PubMed]
7. Fankhauser, C.D.; Curioni-Fontecedro, A.; Allmann, V.; Beyer, J.; Tischler, V.; Sulser, T.; Moch, H.; Bode, P.K. Frequent PD-L1 expression in testicular germ cell tumors. Br. J. Cancer 2015, 113, 411-413. [CrossRef] [PubMed]
8. Scognamiglio, G.; de Chiara, A.; di Bonito, M.; Tatangelo, F.; Losito, N.S.; Anniciello, A.; de Cecio, R.; D’Alterio, C.; Scala, S.; Cantile, M. et al. Variability in immunohistochemical detection of programmed death ligand 1 (PD-L1) in cancer tissue types. Int. J. Mol. Sci. 2016, 17. [CrossRef] [PubMed]
9. Taube, J.M.; Klein, A.; Brahmer, J.R.; Xu, H.; Pan, X.; Kim, J.H.; Chen, L.; Pardoll, D.M.; Topalian, S.L.; Anders, R.A. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20, 5064-5074. [CrossRef] [PubMed]
10. Scognamiglio, G.; Cantile, M.; Scala, S.; Cecere, S.; Russo, F.; Collina, F.; Marra, L.; Sabbatino, F.; Botti, G.; Franco, R. Tissue micro arrays for immunohistochemical detection of inflammatory infiltrates in renal cell carcinoma. Int. J. Clin. Exp. Pathol. 2014, 7, 1175-1179.